What is Tikva Allocell?
Tikva Allocell operates at the vanguard of the biotechnology sector, specializing in the development of next-generation, off-the-shelf T cell therapies. By utilizing its proprietary Allogeneic EBV-Specific T Cell (ALLO EBVST) platform, the company addresses critical gaps in the treatment of refractory cancers and complex autoimmune diseases. Unlike traditional autologous approaches, Tikva Allocell's focus on allogeneic solutions aims to provide readily available, scalable, and cost-effective therapeutic options. This strategic positioning allows the firm to tackle significant unmet medical needs, effectively bridging the gap between laboratory-scale innovation and large-scale clinical application. The company's commitment to engineering safe and potent immunotherapies places it in a competitive position to disrupt current standards of care in oncology.
How much funding has Tikva Allocell raised?
Tikva Allocell has raised a total of $8M across 1 funding round:
Series A
$8M
Series A (2026): $8M, investors not publicly disclosed
Key Investors in Tikva Allocell
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Tikva Allocell?
Following this major enterprise-level funding, Tikva Allocell is expected to prioritize the advancement of its lead candidates through preclinical validation and toward initial human trials. The capital infusion will likely be deployed to enhance manufacturing capabilities for its ALLO EBVST platform, ensuring the scalability required for future clinical phases. Furthermore, the company is anticipated to strengthen its intellectual property portfolio and potentially pursue strategic partnerships to facilitate global market entry. As the firm transitions from a research-focused entity to a clinical-stage developer, the focus will remain on optimizing therapeutic efficacy and safety profiles to meet rigorous regulatory standards. This growth phase is critical for establishing Tikva Allocell as a leader in the off-the-shelf immunotherapy market, ultimately aiming to improve patient outcomes on a global scale.
See full Tikva Allocell company page
